Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (Nasdaq: ARQT) has appointed Christopher “Chris” Peetz to its Board of Directors, effective July 15, 2026. According to Arcutis, the company expects his strategic and operational experience to support its next phase of growth, including advancing and expanding the ZORYVE (roflumilast) franchise and pipeline.
Peetz is co-founder and chief executive officer of Mirum Pharmaceuticals and an entrepreneur-in-residence at Frazier Life Sciences. His career includes leadership roles at Flashlight Therapeutics, Tobira, Jennerex, Onyx Pharmaceuticals, LaSalle Corporate Finance, Abgenix, Solazyme, and board service at Alpine Immune Sciences.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update after U.S. markets close on Wednesday, August 5, 2026. The company will hold a conference call and webcast at 4:30 p.m. ET, with live and replay access available via the Events section of its investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported FDA acceptance of a supplemental New Drug Application for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3–24 months. The FDA set a PDUFA target action date of February 23, 2027.
The sNDA is backed by Phase 2 INTEGUMENT-INFANT and Phase 1 PK data in 3–24 month-olds, showing safety and efficacy over 4 weeks. ZORYVE 0.05% is once-daily, steroid-free and already approved for children aged 2–5 years.
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 61,000 restricted stock units (RSUs) to 9 newly hired employees under its 2022 Inducement Plan. The awards, approved by the Board’s Compensation Committee, were granted July 1, 2026 and will vest 25% annually over four years, following Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) launched a new virtual health platform to expand access to care and its ZORYVE (roflumilast) portfolio for chronic inflammatory skin diseases.
The platform connects eligible individuals with independent, board-certified dermatologists for digital evaluation, diagnosis, and, when appropriate, treatment, complementing traditional in-office dermatology care.
Arcutis (Nasdaq:ARQT) received FDA approval to expand ZORYVE (roflumilast) cream 0.3% for plaque psoriasis to children as young as age 2, including intertriginous areas. ZORYVE is a once-daily, non-steroidal topical for use anywhere on the body, with no duration limits.
The decision is based on a 4-week MUSE study and a 24-week extension in children 2–5, which showed safety and efficacy consistent with prior adolescent and adult trials. This is the seventh FDA approval for ZORYVE in four years. Arcutis highlights broad availability and access programs, including ZORYVE Direct savings and Arcutis Cares assistance.
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 44,000 restricted stock units to six newly hired employees under its 2022 Inducement Plan, effective June 1, 2026.
The RSUs vest over four years, with 25% vesting on each annual anniversary, consistent with Nasdaq Listing Rule 5635(c)(4).
Arcutis (Nasdaq: ARQT)/b) announced publication of new expert consensus guidance on in the American Journal of Clinical Dermatology. Developed by the Arcutis-supported Genital Psoriasis Wellness Consortium, the paper provides age-specific recommendations for pediatric, adult, and older patients, emphasizing routine genital assessment, empathetic communication, and individualized treatment. Genital involvement affects about two-thirds of the nine million people with plaque psoriasis in the United States. The guidance advises minimizing long-term topical corticosteroid use and considering non-steroidal options where appropriate.
Arcutis (Nasdaq: ARQT) announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, held June 8–10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 p.m. ET, with a webcast and 180-day replay on the company website.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported inducement equity grants to 40 newly hired employees under its 2022 Inducement Plan, with a grant date of May 1, 2026.
The company granted 269,000 restricted stock units and options to purchase 70,000 shares. RSUs vest 25% annually over four years. Options vest 25% after one year and monthly over the next three years, have a 10-year term, and an exercise price of $23.35 per share.